This means that no more than 4 clinically significant bleeds, per participant, will be permitted in phase 3 (1 year) of the study. This figure is based on the finding that 5% of patients on full dose standard prophylaxis have more than 3 bleeds per year and that the median number of bleeds in prospective prophylaxis studies in adult patients is between 0 and 3 per year.